Seattle-based Dendreon Corp., which made headlines throughout 2011 due to slower-than-expected sales of prostate cancer vaccine Provenge (sipuleucel-T), agreed to sell its royalty interest related to hepatitis C virus (HCV) drug Victrelis (boceprevir) for $125 million in cash.